411 related articles for article (PubMed ID: 29678735)
21. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
Perazzolo S; Shen DD; Ho RJY
J Pharm Sci; 2022 Mar; 111(3):825-837. PubMed ID: 34673094
[TBL] [Abstract][Full Text] [Related]
22. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
23. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.
Gunaseelan S; Gunaseelan K; Deshmukh M; Zhang X; Sinko PJ
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):518-31. PubMed ID: 19941919
[TBL] [Abstract][Full Text] [Related]
24. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Collins C; Shen DD; Collier AC; Ho RJ
AIDS; 2017 Mar; 31(6):765-770. PubMed ID: 28099191
[TBL] [Abstract][Full Text] [Related]
25. Targeting strategies for delivery of anti-HIV drugs.
Ramana LN; Anand AR; Sethuraman S; Krishnan UM
J Control Release; 2014 Oct; 192():271-83. PubMed ID: 25119469
[TBL] [Abstract][Full Text] [Related]
26. Progress in antiretroviral drug delivery using nanotechnology.
Mallipeddi R; Rohan LC
Int J Nanomedicine; 2010 Aug; 5():533-47. PubMed ID: 20957115
[TBL] [Abstract][Full Text] [Related]
27. Long-acting slow effective release antiretroviral therapy.
Edagwa B; McMillan J; Sillman B; Gendelman HE
Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
[TBL] [Abstract][Full Text] [Related]
28. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.
Cobb DA; Smith NA; Edagwa BJ; McMillan JM
Expert Opin Drug Deliv; 2020 Sep; 17(9):1227-1238. PubMed ID: 32552187
[TBL] [Abstract][Full Text] [Related]
29. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B;
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994
[TBL] [Abstract][Full Text] [Related]
30. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
31. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.
Kudalkar SN; Beloor J; Quijano E; Spasov KA; Lee WG; Cisneros JA; Saltzman WM; Kumar P; Jorgensen WL; Anderson KS
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E802-E811. PubMed ID: 29279368
[TBL] [Abstract][Full Text] [Related]
32. Target Molecules and Delivery Vehicles for Anti-HIV Drugs In vitro and In vivo.
Bolhassani A
Curr Pharm Des; 2018; 24(29):3393-3401. PubMed ID: 29886823
[TBL] [Abstract][Full Text] [Related]
33. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
34. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
Pham K; Li D; Guo S; Penzak S; Dong X
J Control Release; 2016 Mar; 226():88-97. PubMed ID: 26849919
[TBL] [Abstract][Full Text] [Related]
35. Improving combination antiretroviral therapy by targeting HIV-1 gene transcription.
Le Douce V; Ait-Amar A; Forouzan Far F; Fahmi F; Quiel J; El Mekdad H; Daouad F; Marban C; Rohr O; Schwartz C
Expert Opin Ther Targets; 2016 Nov; 20(11):1311-1324. PubMed ID: 27266557
[TBL] [Abstract][Full Text] [Related]
36. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli A; Riva V; Crespan E; Maga G
Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
[TBL] [Abstract][Full Text] [Related]
38. Design strategies for long-acting anti-HIV pharmaceuticals.
Sang Y; Ding L; Zhuang C; Chen F
Curr Opin Pharmacol; 2020 Oct; 54():158-165. PubMed ID: 33176247
[TBL] [Abstract][Full Text] [Related]
39. Lymphatic Delivery of Anti-HIV Drug Nanoparticles.
Nayak Y; Avadhani K; Mutalik S; Nayak UY
Recent Pat Nanotechnol; 2016; 10(2):116-27. PubMed ID: 27502389
[TBL] [Abstract][Full Text] [Related]
40. Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells.
Endsley AN; Ho RJ
AAPS J; 2012 Jun; 14(2):225-35. PubMed ID: 22391788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
